1.Intrafamilial Spread of Hepatitis of virus Ifection.
Journal of the Korean Pediatric Society 1985;28(3):242-250
No abstract available.
Hepatitis*
2.A Clinical Study of Viral Hepatitis in Childhood.
Journal of the Korean Pediatric Society 1984;27(11):1078-1087
No abstract available.
Hepatitis*
3.Clinical Study of Fulminant Hepatitis in Childhood.
Journal of the Korean Pediatric Society 1990;33(7):923-931
No abstract available.
Hepatitis*
4.Clinical Observation of Viral Hepatitis.
Han Ku MOON ; Chang Moo LEE ; Myung Hi SHIN ; Jee Sub OH
Journal of the Korean Pediatric Society 1982;25(11):1097-1105
No abstract available.
Hepatitis*
5.Clinical Observation of Acute Viral Hepatitis in Childhood.
Byung Hak LIM ; Ko Ho JANG ; Sang Geel LEE ; Im Ju KANG
Journal of the Korean Pediatric Society 1985;28(11):1057-1065
No abstract available.
Hepatitis*
7.Guidance for clinical evaluation of drugs used in the tretment of hepatitis.
Ju Seop KANG ; Noon Seoung PARK ; Tae Moo YOO ; Ji Sun YANG ; Dong Sup KIM ; Ju Il KIM ; Kwang Sup KIL
Korean Journal of Medicine 2002;63(2):225-231
No abstract available.
Hepatitis*
8.A prospective cross-sectional study on the prevalence and factors associated with Seroprotection after primary series of Hepatitis B vaccination
Adrienne Michelle B. Lu ; Maria Estela R. Nolasco ; Marilou G. Tan
Pediatric Infectious Disease Society of the Philippines Journal 2018;19(1):3-13
Objectives:
To determine the prevalence and factors associated with seroprotection among children 3 months to 18 years old with primary Hepatitis B vaccination series
Methodology:
This is a prospective cross-sectional study done among children 3 months to 18 years old with complete primary series of Hepatitis B vaccination. Demographic, social and clinical data were correlated with reactivity to antibody to Hepatitis B surface antigen (antiHBs) (>10 IU/L),total antibody to Hepatitis B core antigen (total anti-HBc) and Hepatitis B surface antigen (HBsAg) serologic tests.
Results:
Among 110 subjects from different age groups,52% had seroprotective anti-HBs levels, with the highest noted among infants (3 months-2 years) at 82%, followed by 41% from the childhood group (3-9 years) and 26% from adolescent group (10-18 years). Seventy-four percent of subjects with <5 years interval from vaccination were seroprotected, 26% in subjects after 5-10 years, and 38% at more than 10 years after vaccination with significant difference on multi-logistic regression (p value 0.000/0.020). None of the other factors including gender, geographic area, age at first dose, vaccination schedule, type and place of vaccination were significantly associated with seroprotection.
Conclusion
Fifty-two percent of patients among different age groups were seroprotected. Seroprotection was significantly associated with the interval year after vaccination demonstrated at < 50% 5 years and beyond post-vaccination.
Hepatitis
9.Epidemics of Hepatitis A and E.
Journal of the Korean Medical Association 1998;41(10):1054-1062
No abstract available.
Hepatitis A*
;
Hepatitis*
10.Prevention of Hepatitis B.
Journal of the Korean Pediatric Society 1986;29(4):1-4
No abstract available.
Hepatitis B*
;
Hepatitis*